This IP is a novel RNA‑targeted therapeutic strategy for alveolar rhabdomyosarcoma (ARMS) using CRISPR‑Cas13d to enable the highly specific degradation of the oncogenic mRNA while preserving the wild‑type PAX7 and FOXO1 genes, avoiding the genotoxicity risks associated with DNA‑targeting CRISPR systems.